Portal de Periódicos da CAPES

Prognostic impact of prior local therapy in castration-resistant prostate cancer

2021; Oxford University Press; Volume: 51; Issue: 7 Linguagem: Inglês

10.1093/jjco/hyab019

1465-3621

Mikifumi Koura, Masaki Shiota, Shohei Ueda, Takashi Matsumoto, Satoshi Kobayashi, Keisuke Monji, Eiji Kashiwagi, Ario Takeuchi, Junichi Inokuchi, Kenichiro Shiga, Akira Yokomizo, Masatoshi Eto,

Prostate Cancer Diagnosis and Treatment

Abstract Objective This study aimed to reveal the prognostic values of prior local therapy in first-line therapy using androgen receptor-axis targeting agents (abiraterone or enzalutamide) or docetaxel for castration-resistant prostate cancer (CRPC). Methods The study included 303 patients treated with first-line therapy for non-metastatic and metastatic CRPC. The association between prior local therapy and therapeutic outcome including progression-free survival and overall survival was investigated by univariate and multivariate analyses as well as propensity score-matched analysis. Results In univariate analysis, local prior therapy was associated with a lower risk of all-cause mortality (hazard ratio, 0.56, 95% confidence interval, 0.40–0.79; P = 0.0009). Overall survival, but not progression-free survival, was better among patients with prior local therapy compared with patients without prior local therapy even after multivariate analysis and propensity score-matched analysis. Conclusions This study robustly indicated that prior local treatment was prognostic for overall survival among patients with CRPC. This finding is useful to predict patient prognosis in CRPC.